Table 3.

Clinical characteristics of post-herpetic neuropathic corneal pain patients.

No	Age	Gender (female/male)	Ethnicity	Lateralization (right/left)	Insult	Time between insult and pain onset (weeks)	Duration of pain (weeks)	Ocular Surgery	Accompanying Ocular Disease	Accompanying Systemic Disease	Proparacaine Challenge Test (% relief)	Topical Treatment
1	65	M	Caucasian	L	Herpes zoster	23	20	NA	NA	NA	NA	PFAT, 0.5% loteprednol etabonate
2	56	F	Caucasian	L	Herpes Zoster	40	6	NA	NA	Depression Anxiety and Crohn’s Disease	NA	AST, PFAT, 0.5% loteprednol etabonate
3	88	M	Caucasian	R	Herpes Zoster	63	NA	Cataract Extraction	NA	Osteoarthritis Hyperlipidemia Hypertension Gastroesophageal Reflux	NA	AST, 1% prednisolone acetate
4	66	M	Caucasian	L	Herpes Zoster	2	158	Cataract Extraction and Pars Plana Vitrectomy, Ahmed Glaucoma Valve Implantation	DED Glaucoma (steroid responder)	NA	95.0%	AST, PFAT, 0.5% loteprednol etabonate
5	62	F	Hispanic	R	Herpes Simplex	NA	380	Penetrating Keratoplasty, Ahmed Glaucoma Valve	Glaucoma (steroid responder)	Hyperlipidemia	22.2%	0.5% loteprednol etabonate
6	69	F	Caucasian	L	Herpes Simplex	96	416	Cataract Extraction	DED LSCD	Scleroderma Sjögren’s Syndrome Hyperlipidemia	NA	PFAT
7	89	M	Caucasian	L	Herpes Zoster	46	52	Cataract Extraction	NA	Hyperlipidemia Hypertension Chronic renal failure	0%	AST, 0.5% loteprednol etabonate

AST: Autologous serum tears, DED: Dry eye disease, LSCD: Limbal stem cell deficiency, NA: Not applicable, PFAT: Preservative free artificial tears.